Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Non-myogenic tumors display altered expression of dystrophin (DMD) and a high frequency of genetic alterations.

Oncotarget - 3 Jan 2017

Luce Leonela N, Abbate Mercedes, Cotignola Javier, Giliberto Florencia

Abstract excerpt

DMD gene mutations have been associated with the development of Dystrophinopathies. Interestingly, it has been recently reported that DMD is involved in the development and progression of myogenic tumors, assigning DMD a tumor suppressor activity in these types of cancer. However, there are only few reports that analyze DMD in non-myogenic tumors. Our study was designed to examine DMD expression and genetic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Computational Biology
Share to Databases, Nucleic Acid

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dystrophin

Share to Gene Expression Profiling

Share to Genomics

Share to High-Throughput Nucleotide Sequencing

Share to Neoplasms

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 27391342
DOI: 10.18632/oncotarget.10426
PMCID: PMC5352069

Genes

DMD

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Non-myogenic tumors display altered expression of dystrophin (DMD) and a high frequency of genetic alterations.PMID 27391342Read ↗

Downregulation of dystrophin expression occurs across diverse tumors, correlates with the age of onset, staging and reduced survival of patientsSemantic proximity Read ↗

Dystrophin is a tumor suppressor in human cancers with myogenic programs.Semantic proximity Read ↗

The Duchenne muscular dystrophy gene and cancer.Semantic proximity Read ↗

Duchenne muscular dystrophy gene expression is an independent prognostic marker for IDH mutant low-grade glioma.Semantic proximity Read ↗

Dlk1-Dio3 cluster miRNAs regulate mitochondrial functions in Duchenne muscular dystrophySemantic proximity Read ↗

The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations.Semantic proximity Read ↗

Multi-level omics analysis in a murine model of dystrophin loss and therapeutic restoration.Semantic proximity Read ↗

Cancer phenotype in myotonic dystrophy patients: Results from a meta-analysis.Semantic proximity Read ↗

Late-Stage Skeletal Muscle Transcriptome in Duchenne muscular dystrophy shows a BMP4-Induced Molecular SignatureSemantic proximity Read ↗

DNA damage, somatic aneuploidy, and malignant sarcoma susceptibility in muscular dystrophies.Semantic proximity Read ↗

Exploring Dystrophin Expression and Mutations in the DMD and Dystrophin-Glycoprotein Complex Genes as Prognostic Factors in Leiomyosarcomas.Semantic proximity Read ↗

Consistent MYORG and STRADB Downregulation in DMD and LGMD: Rationale for Deoxygalactonojirimycin Repurposing in Dystrophic and Aging MuscleSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.